Evidence map›Paper›PMID 42118449›Full record

ArticleInternational journal of hematology2026

T-cell fitness, metabolic tumor volume, and serum LDH levels are associated with response to axicabtagene ciloleucel.

Risa Nishiyama, Anna Hiratsuka, Tetsuro Ochi, Akiko Miyagi Maeshima, Wataru Takeda, Kimiteru Ito, Yu Aruga, Chiaki Ikeda, Hirotaka Matsui, Noriko Iwaki and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Risa NishiyamaDepartment of Hematology, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan.
Anna HiratsukaDepartment of Hematology, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan.
Tetsuro OchiDepartment of Hematology, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan.
Akiko Miyagi MaeshimaDepartment of Pathology, National Cancer Center Hospital, Tokyo, Japan.
Wataru TakedaDepartment of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
Kimiteru ItoDepartment of Diagnostic Radiology, National Cancer Center Hospital, Tokyo, Japan.
Yu ArugaDepartment of Laboratory Medicine, National Cancer Center Hospital, Tokyo, Japan.
Chiaki IkedaDepartment of Laboratory Medicine, National Cancer Center Hospital, Tokyo, Japan.
Hirotaka MatsuiDepartment of Laboratory Medicine, National Cancer Center Hospital, Tokyo, Japan.
Noriko IwakiDepartment of Hematology, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan.
Suguru FukuharaDepartment of Hematology, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan.
Wataru MunakataDepartment of Hematology, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan.
Shinichi MakitaDepartment of Hematology, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan. smakita@ncc.go.jp.
Koji IzutsuDepartment of Hematology, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Axicabtagene ciloleucel (axi-cel) has demonstrated efficacy and safety in relapsed/refractory large B cell lymphoma (r/r LBCL). However, evidence from Asian populations remains limited.This study evaluated patients with r/r LBCL who underwent leukapheresis for axi-cel between April 2023 and December 2025. Fifty-five patients were evaluable for safety, including 38 treated in the second-line setting (2L). CRS occurred in 53 (96%), with grade ≥ 3 in 6 (10%). ICANS occurred in 17 (31%), with grade ≥ 3 in 6 (11%). Compared with patients receiving third-line or later (3L +) treatment, 2L patients experienced higher rates of grade ≥ 3 CRS (13% vs. 6%) and any-grade ICANS (37% vs. 18%). Among the 55 patients, the overall response rate was 91%. After a median follow-up of 14.5 months, the 1.5-year PFS and OS rates were 63.1% and 83.1%, respectively. 2L showed numerically higher PFS than 3L + (1.5-year PFS: 64.9% vs. 57.0%; HR: 1.75; p = 0.248). Multivariate analysis identified three independent risk factors for PFS: low peripheral blood CD8

Indexed as

Biological ProductsL-Lactate DehydrogenaseLymphoma, Large B-Cell, DiffuseT-LymphocytesTumor BurdenAdultAgedAged, 80 and overFemaleHumansLeukapheresisMaleMiddle AgedTreatment Outcomeaxicabtagene ciloleucelBiological ProductsL-Lactate DehydrogenaseAxicabtagene ciloleucelCytokine release syndromeImmune effector cell-associated neurotoxicity syndromeRelapsed/refractory large B-cell lymphomaT-cell fitness

Identifiers

PMID42118449

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.